Health Care Reform 2009

From the Publishers of the New England Journal of Medicine

Comparative Effectiveness rss

Industry Influence on Comparative-Effectiveness Research Funded through Health Care Reform(0)

November 18, 2009

Harry P. Selker, M.D., M.S.P.H., and Alastair J.J. Wood, M.D.
Much attention has been focused on the ongoing efforts in Washington to pass a health care reform bill. Comprehensive health care should reduce the use of ineffective and suboptimal medical interventions and investigations in order to improve medical care and reduce wasted expense.

Full Story

New, but Not Improved? Incorporating Comparative-Effectiveness Information into FDA Labeling

Randall S. Stafford, M.D., Ph.D., Todd H. Wagner, Ph.D., and Philip W. Lavori, Ph.D.
New technologies, including prescription drugs and medical devices, are a major driver of increases in U.S. health care expenditures, which have grown by an estimated 71% since 2000.1 The U.S. market for drugs and devices is regulated by the Food and Drug [...]

Comparative Effectiveness — Thinking beyond Medication A versus Medication B

Kevin G. Volpp, M.D., Ph.D., and Anup Das
The American Recovery and Reinvestment Act of 2009 (ARRA), the stimulus package signed into law by President Barack Obama on February 17, 2009, directs $1.1 billion to support “the development and dissemination of research assessing the comparative effectiveness of health care treatments and strategies, including through efforts that [...]

Prioritizing Comparative-Effectiveness Research — IOM Recommendations

John K. Iglehart
Directed by Congress to rapidly develop a list of broad-based priorities for the Department of Health and Human Services (DHHS) to consider as it implements a new agenda for comparative-effectiveness research (CER), the Institute of Medicine (IOM) released a report recommending a portfolio of 100 study topics related to a range of diseases, [...]


More in this category